APSR2026-669

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-057
P112
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1210893-46904-APSR TB + Hepatic Dysfunctiontx_433517.pdf
Format: PDF Only
06. Tuberculosis
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Heamah Krishnan * Hospital Sultanah Nur Zahirah Medical/Respiratory Terengganu Malaysia
Azlina Samsudin - Hospital Sultanah Nur Zahirah Medical/Respiratory Terengganu Malaysia
Nurul Majidah Abdul Razak - Hospital Sultanah Nur Zahirah Medical/Respiratory Terengganu Malaysia
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Heamah
Krishnan
heamahkrishnan@gmail.com
+60178691008
31-40
Malaysia
Case Report
Pulmonary Tuberculosis with Hepatic Tuberculosis ; Diagnostic Challenges and the Role of Adjunctive Corticosteroids.
Maximum 25 words
Abstract Content
 
 
 
 
Tuberculosis (TB) remains a major global health burden. Extrapulmonary TB accounts for 15–20% of cases in immunocompetent individuals and up to 50% in immunocompromised patients. Hepatic involvement is usually seen in disseminated or miliary TB and often presents with non-specific features such as fever, weight loss, hepatomegaly, and deranged liver function tests (LFTs). Radiological findings are variable and may mimic malignancy, abscess, or drug-induced liver injury (DILI). Concomitant hepatic involvement in active pulmonary TB is uncommon and frequently under-recognised.
A 30-year-old previously healthy woman presented with one month of fever (up to 39°C), two months of cough, night sweats, and 6 kg weight loss. She had close contact with individuals diagnosed with pulmonary TB. Investigations showed elevated inflammatory markers (CRP 124 mg/L, ESR 67 mm/hr) and deranged LFTs (AST 165 U/L, ALT 146 U/L). Sputum AFB was negative, but GeneXpert confirmed Mycobacterium tuberculosis. Due to baseline liver dysfunction, she was started on a non-hepatotoxic anti-TB regimen (SEL). Despite treatment, LFTs worsened. Prednisolone (0.5 mg/kg/day) was initiated, resulting in gradual improvement of liver enzymes. She was subsequently changes to standard anti-TB therapy (RHEL). Clinically, she improved with resolution of symptoms and normalisation of LFTs. Follow-up imaging showed improvement of splenic anechoic lesions.
Hepatic dysfunction in TB poses diagnostic challenges, particularly in distinguishing hepatic TB from DILI and paradoxical reactions. In this case, pre-treatment LFT derangement, negative alternative workup, and clinical response supported hepatic TB rather than DILI. Hepatic involvement occurs via haematogenous spread, leading to granuloma formation. Although common in disseminated TB, it is often clinically silent and under-recognised. Management follows standard anti-TB therapy. While corticosteroids are established in TB meningitis and selectively used in pericardial TB, their role in hepatic TB is unclear. However, in selected cases with significant inflammatory involvement, short-course corticosteroids may be beneficial, with careful monitoring.
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1210893-37089-CXR_381173.jpg
JPG or JPEG or PNG format ONLY
Hepatic Tuberculosis,Liver Dysfunction,Corticosteroid
maximum 3 keywords and no abbreviations, separated by commas
No disclosure
308